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Summary  The  costs,  beneﬁts  and  risks  associated  with  diagnostic  imaging  investigations  for
epilepsy surgery  necessitate  the  identiﬁcation  of  an  optimal  pathway  in  the  pre-surgical  workup.
In order  to  assess  the  added  value  of  additional  investigations  a  full  cost-effectiveness  evalua-
tion should  be  conducted,  taking  into  account  all  of  the  life-time  costs  and  beneﬁts  associated
with undertaking  additional  investigations.  This  paper  considers  and  applies  the  appropriate
framework  against  which  a  full  evaluation  should  be  assessed.
We conducted  a  systematic  review  to  evaluate  the  progression  of  the  literature  through  this
framework,  ﬁnding  that  only  isolated  elements  of  added  value  have  been  appropriately  evalu-
ated. The  results  from  applying  the  full  added  value  framework  are  also  presented,  identifying
an optimal  strategy  for  pre-surgical  evaluation  for  temporal  lobe  epilepsy  surgery.  Our  results
suggest that  additional  FDG—PET  and  invasive  EEG  investigations  after  an  initially  discordant
MRI and  video-EEG  appears  cost-effective,  and  that  the  value  of  subsequent  invasive-EEGs  is
closely linked  to  the  maintenance  of  longer-term  beneﬁts  after  surgery.It is  integral  to  the  evaluation  of  imaging  technologies  in  the  work-up  for  epilepsy  surgery
that the  impact  of  the  use  of  these  technologies  on  clinical  decision-making,  and  on  further
treatment decisions,  is  considered  fully  when  informing  cost-effectiveness.
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Box  1  The  Schaafsma  framework
1.  The  ﬁrst  step  of  evaluation  is  to  identify  the  test
characteristics  of  the  imaging  technology.  These  are
the  parameters  that  deﬁne  the  clinical  ability  of  the
technology,  for  example  the  diagnostic  accuracy,
and  the  sensitivity  and  speciﬁcity.
2.  The  second  considers  the  clinical  value  of  a  test.
As  the  tests  involved  in  pre-treatment  workup  are
usually  used  in  sequence  the  additional  information
provided  by  the  test  to  the  decision  maker  must  be
considered,  rather  than  the  test’s  ability  in  isola-
tion.
3.  Thirdly  the  resultant  clinical  outcome  is  important
to  the  evaluation  of  the  technology  being  consid-
ered.  As  the  justiﬁcation  for  additional  imaging
tests  is  not  the  direct  output  of  the  test  but  the
potential  access  to  beneﬁcial  medical  treatments,
such  as  surgery,  it  is  vital  to  consider  the  poten-
tial  clinical  outcomes  of  the  range  of  different
treatment  options  available  once  the  test  result  is
deﬁned.
4.  Finally  is  the  role  of  cost-effectiveness. Schaafsma



























CT),  Positron  Emission  Tomography  (PET),  Single-Photon
mission  Computed  Tomography  (SPECT)  and  Magnetic
esonance  Imaging  (MRI)  technologies  as  well  as  greatly
ncreased  demand  by  health  care  providers  (Iglehart,  2006).
n  any  area  of  signiﬁcant  spend  it  is  important  to  ensure
hat  growth  is  based  on  both  clinical  evidence  as  well  as
alue  for  money.  Consideration  of  value  for  money  ensures
hat  additional  expenditure  results  in  the  greatest  potential
ain  in  health.
However,  to  date  there  has  been  little  research  con-
ucted,  in  epilepsy  or  more  generally,  that  has  sufﬁciently
onsidered  the  value  for  money  of  imaging  strategies  avail-
ble  through  cost-effectiveness  methods.  (Schaafsma  et  al.,
009;  Burch  et  al.,  2012a)  The  limited  maturity  of  the  exist-
ng  research  may  partly  be  explained  by  the  difﬁculty  in
ssessing  the  value  of  an  additional  medical  imaging  tech-
ology,  and  lack  of  an  accepted  standard  of  analysis.  The
ifﬁculty  in  assessing  added  value  in  this  context  is  largely
 result  of  the  difﬁcult  interpretation  of  a  test  results
Hogstrom  and  Sverre,  1996),  difﬁculty  in  interpreting  and
ssessing  diagnostic  accuracy  (Burch  et  al.,  2012b),  and  the
inking  of  these  results  to  the  long  term  clinical  outcomes
Schaafsma  et  al.,  2009;  Trikalinos  et  al.,  2009).
To  date  there  has  been  little  consideration  of  the  appro-
riate  methods  with  which  to  consider  the  added  economic
alue  of  imaging  technologies  in  general,  with  the  majority
ocussing  solely  on  the  clinical  value  alone.  Authors  such  as
chaafsma  et  al.  (2009)  and  Fryback  and  Thornbury  (1991)
ave  presented  hierarchies  of  evidence  required  to  con-
ider  the  added  value  of  a  diagnostic  technology.  A  common
eature  of  these  hierarchies  is  that  the  lower  end  consid-
rs  assessments  of  diagnostic  performance  with  the  higher
tages  considering  change  in  clinical  outcome  and  cost-
ffectiveness.  In  general,  the  evaluation  of  diagnostics  is
ypically  limited  to  the  lower  end  of  the  hierarchy  (Trikalinos
t  al.,  2009).  The  frameworks  highlight  that  the  added  value
f  a  diagnostic  technology  depends  not  only  on  diagnostic
ccuracy  but  also  how  the  results  impact  on  subsequent
reatment  decisions,  as  well  as  the  associated  ﬁnal  clinical
utcomes.  We  will  consider  the  application  of  the  Schaafsma
ierarchy,  shown  in  Box  1,  to  the  example  of  pre-surgical
orkup  for  temporal  lobe  epilepsy  surgery.
Surgical  intervention  to  resect  the  epileptic  focus  has  the
otential  to  signiﬁcantly  improve  patient  outcomes  (NICE,
012).  Medical  imaging  technologies  are  increasingly  used
o  try  to  identify  structural  or  functional  changes  to  help
ocalise  the  likely  site  of  the  seizure  focus  and  inform  deci-
ions  about  further  investigation  and  whether  and  how  to
roceed  with  surgery.  Due  to  the  costs  and  potential  adverse
vents  associated  with  these  medical  imaging  techniques
he  optimal  selection  and  order  of  the  imaging  tests  is
mportant.  A  systematic  review  of  the  literature  found  that
o  research  had  sufﬁciently  considered  the  added  value  of
maging  technologies  in  the  pre-surgical  workup  of  epilepsy
atients,  using  cost-effectiveness  methods  (Burch  et  al.,
012a).
An  additional  review  was  conducted  to  evaluate  previ-
us  research  into  the  clinical  value  of  tests  (stage  2  of  the
chaafsma  hierarchy)  in  this  area  (Burch  et  al.,  2012a)  The
eview  found  a  single  study,  by  Uijl  et  al.  (2007), which
ssessed  the  impact  of  additional  investigations  (FDG—PET




dof  the  information  collected  in  the  previous  stages
is  the  use  of  a  full  cost-effectiveness  evaluation.
o  surgery  after  discordant  video-EEG  and  MRI  ﬁndings.  The
tudy  considered  the  short-term  outcome  following  surgery
stages  1,  2  and  3);  costs  and  longer-term  outcomes  were
ot  considered.
This  paper  uses  the  study  by  Uijl  et  al.  in  a  worked  exam-
le  to  present  a  framework  for  assessing  the  full  added  value
f  additional  imaging  tests  in  the  case  of  pre-surgical  workup
or  temporal  lobe  epilepsy  surgery,  using  the  Schaafsma
ramework  (Box  1).  The  framework  will  be  used  to  evalu-
te  the  cost-effectiveness  of  the  range  of  clinical  strategies
resented  by  Uijl  et  al.,  the  uncertainty  in  these  results  will
e  explored  through  the  use  of  a  scenario  analysis  as  well  as
robabilistic  sensitivity  analysis  (PSA).
ethods
 decision  model  was  constructed  to  allow  an  evaluation
f  added  value  in  the  pre-surgical  workup  of  patient  with
pilepsy  consistent  with  the  Schaafsma  framework  (Box  1).
 decision  model  is  a  quantitative  approach  used  to  combine
vidence  from  a  variety  of  sources  to  inform  the  evaluation
f  added  value.  It  does  so  through  the  consideration  of
he  diagnostics  outcomes  of  the  tests  alongside  the  longer
erm  implications  of  the  range  of  decision  strategies.
his  approach  facilitates  an  assessment  of  the  relative
alue  of  each  strategy  available  to  the  decision  maker,
n  terms  of  costs  and  health  related  quality  of  life  of  the
atient,  and  ultimately  allows  the  optimal  strategy  to  be
dentiﬁed  through  a  consideration  of  the  cost-effectiveness
f  each  strategy.  Uncertainty  in  the  model  inputs  can  be
ropagated  to  allow  for  a  consideration  of  the  likelihood
nd  implications  of  an  incorrect  decision  being  made  by  the
ecision  maker  (Drummond  et  al.,  2005).
The  added  clinical  and  economic  value  of  diagnostic  testing  for  
Box  2  Strategies  evaluated
Strategy  1)—–MM No  additional  tests  performed,  and  all
patients  receive  medical  management  (MM).
Strategy  2)—–PET  FDG—PET  is  performed;  if  the  result
of  this  test  does  not  lead  to  a  positive  (S+)  or  nega-
tive  (S−)  decision  to  undertake  surgery  and  still  leaves
the  clinician  uncertain  whether  to  proceed  to  surgery
(S?),  then  no  further  tests  are  performed.  The  analyses
consider:
-  Patients  are  offered  surgery  if  S+  after  FDG—PET.
-  Patients  are  offered  medical  management  if  S−  or  S?
after  FDG—PET.
Strategy  3)—–PET  and  iEEG  FDG—PET  is  performed;  if
the  result  of  this  test  does  not  lead  to  a  clear  deci-
sion  on  whether  the  patient  should  proceed  to  surgery
(S?),  iEEG  is  offered.  The  analyses  consider:
-  Patients  are  offered  surgery  if  S+  after  FDG—PET.
-  Patients  are  offered  medical  management  if  S-  after
FDG—PET.
-  Patients  are  offered  invasive  EEG  if  S?  after  FDG—PET.
The  result  of  this  test  determines  the  provision  of
treatment  (S+  after  invasive  EEG  implies  a  decision  to
























































This  case  study  considers  the  optimal  medical  imaging
strategy  for  patients  considered  eligible  for  temporal  lobe
epilepsy  surgery,  the  population  evaluated  in  the  Uijl  study.
The  decision  model  focuses  on  the  appropriate  course  of
action  given  discordant  ﬁndings  of  initial  MRI  and  EEG,  and
speciﬁcally  assesses  the  added  clinical  and  economic  value
of  undertaking  further  imaging.
The  decision  problem  addressed  is  limited  to  three  pos-
sible  medical  investigation  strategies,  given  non-localising
or  discordant  ﬁndings  from  initial  video-EEG  and  MRI  scans,
such  that  the  clinician  does  not  deem  there  to  be  sufﬁ-
cient  information  to  proceed  with  surgery  or  to  discount
it.  The  strategies  are:  (1)  no  further  imaging  tests  applied,
(2)  the  use  of  FDG—PET  alone,  or  (3)  the  use  of  FDG—PET
followed  by  invasive  EEG  (iEEG)  for  patients  for  whom  the
decision  to  proceed  to  surgery  is  still  unclear  after  FDG—PET.
We  acknowledge  that  these  strategies  represent  a  poten-
tial  over-simpliﬁcation  of  the  available  clinical  pathways  in
both  the  range  of  technologies  available  (for  example  mag-
netoencephalography  or  the  more  sensitive  methods  such  as
3T  scanning),  and  the  potential  for  repetition  of  some  tests
to  facilitate  a  better  understanding  of  the  seizure  focus.
The  strategies  used  in  the  decision  model  were  chosen  due
to  the  lack  of  literature  beyond  that  of  Uijl  that  sufﬁciently
considers  the  role  of  added  value,  and  as  such  represent  the
only  strategies  of  which  sufﬁcient  information  was  available
to  facilitate  inclusion  into  a  decision  model.  These  alterna-
tive  approaches  to  patient  management  are  used  to  deﬁne
a  series  of  separate  strategies,  detailed  in  Box  2.
The  decision  model  developed  has  two  main  compo-
nents:  a  short-term  element,  which  characterises  the  period
y
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ver  which  these  localisation  strategies  are  applied  and,  if
ppropriate,  surgery  is  conducted,  and  a  long-term  element,
hich  considers  the  costs  and  outcomes  over  the  remaining
ifetime  of  the  patient.  In  developing  and  populating  the
odel,  we  sought  to  incorporate  evidence  and  treatment
ecommendations  from  the  most  recent  NICE  clinical  guide-
ine  on  epilepsy  (NICE,  2012).
The  short-term  element  reﬂects  the  short-term  clinical
utcomes  and  adverse  events  associated  with  each  of  three
ocalisation  strategies,  as  informed  by  Uijl  et  al.  (2007).  For
odelling  purposes  this  is  represented  as  a  decision  tree,
s  depicted  in  Fig.  1  below,  and  assumes  a  time-span  of  one
ear.  The  decision  tree  evaluates  the  strategies  described
n  Box  2, such  that  patients  are  ﬁrst  considered  in  the
odel  after  having  an  MRI  and  video-EEG  that  has  not  led  to
 conclusive  decision  about  eligibility  for  surgery.  Patients
ow  through  the  model,  their  path  determined  by  a  set
f  clinical  decisions  (represented  by  decision  nodes) and
ransition  probabilities  (probability  nodes). At  the  end  of
he  decision  tree  all  patients  have  either  died  or  enter  the
ong-term  model.  Further  assumptions  were  necessary  to
pply  the  results  of  Uijl  et  al.  and  are  discussed  elsewhere
Burch  et  al.,  2012a).
The  short-term  model  links  decisions  to  undergo  surgery
ith  the  immediate  outcomes:  those  who  survive  surgery
an  either  (i)  achieve  seizure  freedom  (SF)  for  a  year  after
he  treatment  option  was  provided,  or  (ii)  have  a  disabling
eizure  (DS)  within  that  year.  Our  analysis  uses  the  term
disabling  seizure’  to  represent  a  patient  in  Engel  class  2
r  higher,  consistent  with  the  literature  used  to  inform  the
ecision  model  (Choi  et  al.,  2008).  Patients  who  had  seizures
hat  were  not  disabling  (and  as  such  would  be  classiﬁed  as
ngel  class  1)  were  included  in  the  SF  states.  All  patients
ere  assumed  to  receive  anti-epileptic  drugs  (AED)  treat-
ent  in  the  short-term  with  full  compliance  assumed  for  all
rocedures.
The  long-term  model  aims  to  characterise  the  lifetime
rognosis  for  patients  leaving  the  short-term  model,  its
tructure  is  informed  by  Choi  et  al.  (2008)  (see  Fig.  2  below
or  the  model  structure).  Patients  enter  directly  from  the
hort-term  model  having  either  achieved  SF  for  the  ﬁrst  year
fter  evaluation  or  having  a  DS  within  that  year,  excluding
hose  patients  who  died  during  the  short-term  model.
Our  base  case  model  assumes  that  after  patients  are
ssessed  for  suitability  of  TLE  surgery,  and  have  surgery
r  remain  on  medical  management  alone,  they  face  a  long
erm  possibility  of  remaining  seizure  free  dependant  on  the
reatment  received.  The  chance  of  remaining  seizure  free  is
tratiﬁed  into  three  time  periods  from  the  time  of  assess-
ent  to  represent  the  variable  nature  of  the  probability
f  remission  identiﬁed  in  much  of  the  literature  (Schwartz
t  al.,  2006;  Hemb  et  al.,  2013).  These  periods  are  the  ﬁrst
ear  after  assessment/surgery,  from  the  end  of  the  ﬁrst  year
o  the  start  of  the  ﬁfth  year,  and  from  the  ﬁfth  year  to  the
nd  of  the  patient’s  lifetime.  The  values  are  based  of  the
andom-effects  models  estimated  by  Choi  et  al.  (2008)  from
ve  studies  all  of  which  estimated  the  long  term  probabil-
ty  of  relapse  in  both  the  surgery  and  medical  managementPatients  who  are  long-term  SF  (having  more  than  two
ears  of  seizure  freedom)  have  the  possibility  of  stopping
reatment  with  AEDs  (with  a  certain  probability),  as  is
778  S.  Hinde  et  al.
Fig.  1  Structure  of  the  short-term  decision  tree.  DS:  experiencing  
management;  SF:  seizure-free.


























oat  least  one  disabling  seizure;  iEEG:  invasive  EEG;  MM:  medical
onsistent  with  NICE  clinical  guidelines  (NICE,  2008).  From
ll  states  in  the  long-term  model  patients  face  the  risk  of
eath,  with  the  risk  greater  for  patients  who  have  had  a  dis-
bling  seizure  in  that  year  than  those  who  are  seizure-free.
To  inform  a  decision  model  data  is  required  on  a  range  of
arameters  which  can  be  considered  in  three  broad  groups:
i)  transition  probabilities,  (ii)  resource  use  and  costs  and
iii)  quality  of  life.  Appendix  A  and  B  Table  A1  presents
he  values  assigned  in  the  model  to  the  relevant  inputs,
longside  the  conﬁdence  intervals  and  distributions  used
o  represent  uncertainty  in  the  parameter  estimates.  Fur-
her  details  are  provided  in  the  full  technical  report.  (Burch
t  al.,  2012a) Uncertainty  in  the  decision  model  inputs  is
nvestigated  through  the  use  of  PSA,  which  characterises
he  uncertainty  in  each  of  the  parameters  and  propagates  it
hrough  the  decision  model.
Resource  use  and  costs  are  estimated  from  the  perspec-
ive  of  the  NHS  and  Personal  Social  Services,  expressed  in  UK
ounds  sterling  at  a  2010  price  base.  Health  outcomes  are
xpressed  in  terms  of  Quality  Adjusted  Life  Years  (QALYs),  a
easure  combining  health  related  quality  of  life  with  dura-
ion  of  life.  Both  costs  and  outcomes  are  discounted  using  a
.5%  annual  discount  rate  consistent  with  current  guidelines
NICE,  2008).cenario  analysis
n  important  factor  in  the  decision  model  is  the  propensity
f  patients  who  have  surgery  to  remain  seizure-free  in  the



















































tThe  added  clinical  and  economic  value  of  diagnostic  testing
long-term.  As  discussed  above  our  base-case  analysis  uses
the  ﬁndings  from  Choi’s  synthesis  to  inform  the  long-term
probability  of  patients  remaining  seizure-free  after  surgery.
To  explore  the  role  of  long-term  seizure  freedom  on  the
results  of  the  cost-effectiveness  analysis,  a  highly  conserva-
tive  scenario  analysis  was  constructed  in  which  the  beneﬁts
of  surgery  were  maintained  for  one  year  only  after  the  pro-
cedure,  at  which  point  the  probability  of  maintaining  seizure
freedom  is  assumed  to  be  the  same  as  patients  who  did  not
receive  the  surgery.  This  scenario  represents  a  conservative
alternative  to  the  base-case;  however  it  is  used  to  highlight
the  importance  of  surgery  efﬁcacy  in  the  evaluation  of  the
cost-effectiveness  of  medical  imaging  strategies  considered.
It  is  therefore  a  useful  tool  in  highlighting  the  role  of  the
assessment  of  long  term  clinical  outcomes,  as  represented
by  level  3  of  the  Schaafsma  structure  (Box  1).  The  results
of  various  other  scenarios  are  reported  in  the  accompanying
technical  report  (Burch  et  al.,  2012a).
Results
We  present  the  results  of  the  analysis  in  a  number  of  ways,
beginning  with  an  assessment  of  the  cost-effectiveness  of
the  strategies  considered.  We  then  consider  the  implications
of  the  uncertainty  associated  with  the  decision  model  both
in  terms  of  parameter  uncertainty  as  well  as  the  scenario
analysis  discussed  above.
Table  1  presents  the  estimated  mean  total  costs,  life
years  and  QALYs  per  patient  derived  from  the  decision
model.  The  strategies  themselves  are  ranked  in  terms  of
ascending  costs  and  associated  differences  in  costs  and
QALYs  are  also  presented  relative  to  the  next  lowest  cost
strategy  in  the  table.  These  values  are  calculated  from
the  decision  model  presented  in  the  previous  section.  The
results  of  the  main  analysis  show  that  the  lifetime  costs  to
the  health  care  provider  associated  with  the  three  scenar-
ios  were  between  £23,775  and  £27,696.  The  majority  of  this
cost  difference  is  made  up  by  the  cost  of  the  additional
surgical  procedures  arising  from  the  additional  tests  pro-
vided  in  Strategies  2  and  3  as  well  as  the  costs  of  the  tests
themselves.
The  quality  of  life  and  expected  survival  of  patients  con-
sidered  under  each  treatment  strategy,  represented  in  QALYs
over  the  patient’s  lifetime,  is  between  12.88  and  14.91,
largely  driven  by  the  relative  beneﬁt  to  patients  who  are,
as  a  result  of  outcomes  from  the  medical  imaging  tests,
provided  with  surgery.
In  additon,  in  Table  1  we  present  the  Incremental
Cost-Effectiveness  Ratios  (ICER).  The  ICER  represents  the
additional  cost  per  additional  QALY  gained  with  a  more
costly  and  effective  strategy,  relative  to  the  next  most  cost-
effective  alternative.  The  ICER  is  calculated  as:
ICER  = incremental  cost
incremental  QALY
NICE  deﬁne  a  cost-effectiveness  threshold,  below  which  a
technology  is  considered  cost-effective,  of  £20,000—£30,000
per  QALY  (NICE,  2008).  The  results  in  Table  1  show  that,  at
this  threshold  range,  Strategy  3  is  the  most  cost-effective
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reatest  gain  in  QALYs  within  the  cost-effectiveness  thresh-
ld.
We  also  present  the  probability  of  each  strategy  being
ost-effective  at  two  different  threshold  values  (£20,000
nd  £30,000,  Table  1).  This  probability  is  calculated  using
SA  methods  to  take  account  of  uncertainty  in  many  of  the
ecision  model  parameters.  These  results  show  that  in  our
ain  analysis  Strategy  3  (i.e.  the  use  of  FDG—PET  and  inva-
ive  EEG)  is  the  most  likely  to  be  cost-effective  (probabilities
f  0.83  and  0.84).
As  discussed  previously,  an  additional  scenario  was  also
onsidered  whereby  the  beneﬁts  associated  with  surgery
ere  assumed  to  be  maintained  for  only  one  year  after  the
rocedure,  in  contrast  to  the  main  analysis  in  which  these
eneﬁts  were  assumed  to  be  maintained  over  the  patient’s
ifetime.  The  results  based  on  this  scenario  are  shown  in  the
ower  half  of  Table  1.
The  results  of  the  scenario  analysis  show  a  relatively
mall  change  in  the  associated  costs  of  each  strategy,  as
 result  of  an  increase  in  the  number  of  patients  expected
o  receive  AEDs  in  the  long  term.  In  addition,  Strategies  2
nd  3  are  associated  with  a  reduction  in  the  estimated  life
ear  (and  as  a  result  quality  of  life)  beneﬁts  compared  to
he  main  analysis.  This  is  as  a  direct  result  of  fewer  beneﬁts
eing  realised  by  those  patients  who  have  surgery,  due  to
ncreased  probability  of  future  disabling  seizures.
Under  this  scenario  the  cost-effectiveness  of  Strategies
 and  3  become  less  favourable  (shown  by  the  increased
CERs).  Furthermore,  at  both  cost-effectiveness  threshold
alues  Strategy  3  is  no  longer  cost-effective,  as  its  ICER  of
32,876  is  above  both  thresholds.  Consequently,  in  this  sce-
ario,  Strategy  2  appears  the  most  cost-effective  strategy.
owever,  the  error  probability  associated  with  this  strategy
s  63—64%,  and  as  such  there  exists  signiﬁcant  uncertainty
oncerning  the  optimal  strategy.
To further  understand  these  results  Table  2 provides  a
ange  of  descriptive  statistics  from  the  decision  model,
onsidering  both  the  main  analysis  and  the  scenario.  The
able  presents  the  prevalence  of  surgery,  the  likelihood  of
atient  becoming  seizure-free  after  treatment  and  the  aver-
ge  long  term  period  of  seizure  freedom  for  each  of  the
trategies  considered.
In  the  base  case  decision  model,  as  expected,  the  proba-
ility  of  having  surgery  increases  as  more  tests  are  available
o  the  clinical  decision  maker.  These  range  from  0  in  Strat-
gy  1,  where  there  is  insufﬁcient  information  to  proceed  to
urgery  but  no  further  tests  available,  to  0.68  for  Strategy
,  where  both  FDG—PET  and  invasive-EEG  tests  are  avail-
ble.  The  probability  of  being  seizure-free  at  the  end  of
he  ﬁrst  year  of  analysis  is  strongly  linked  to  the  proportion
f  patients  that  receive  surgical  intervention;  thus  Strat-
gy  3  results  in  the  largest  potential  for  short  term  seizure
reedom.  As  the  scenario  analysis  does  not  impact  on  the
hort-term  decision  tree  the  probability  of  having  surgery
nd  the  probability  of  being  seizure-free  at  the  end  of  the
hort-term  model  (i.e.  1  year  after  clinical  initiation)  are
he  same  in  the  scenario  as  in  the  base  case.
The  overall  time  a  patient  will  spend  in  the  seizure-free
tate  is,  alongside  mortality,  the  main  factor  that  will  inﬂu-
nce  the  QALY  gain  associated  with  each  strategy  and  hence
he  relative  cost-effectiveness  of  the  strategies.  Seizure-
ree  time  is,  however,  strongly  dependent  on  the  assumption
780  S.  Hinde  et  al.
Table  1  Cost-effectiveness  results  (base-case  versus  alternative  scenario),  see  Box  2  for  Strategy  deﬁnitions.








Strategy  1—–MM  23,775  18.78  12.88  —  —  —  0.14  0.13
Strategy 2—–PET  26,621  19.80  14.58  2846  1.70  1679  0.03  0.03
Strategy 3—–PET  and  iEEG 27,696  20.01  14.91  1075  0.33  3227  0.83  0.84
Alternative scenario  (no  long-term  beneﬁts  of  surgery)
Strategy  1—–MM 23,726  18.78  12.89  —  —  —  0.36  0.25




















































aStrategy 3—–PET  and  iEEG  28,416  18.84  13.23  12
f  continued  medical  beneﬁt  of  surgery,  as  tested  by  the  sce-
ario,  where  the  duration  of  beneﬁt  is  reduced  from  lifetime
o  one  year  only.  As  no  patients  in  Strategy  1  receive  surgery
he  duration  is  unchanged  in  the  scenario.  In  contrast,
trategies  2  and  3  the  expected  seizure-free  durations  are
igniﬁcantly  reduced  by  this  change  in  assumption  (by  8.04
nd  9.76  years,  respectively).  While  the  seizure-free  dura-
ion  is  signiﬁcantly  reduced  the  relative  rank  is  unchanged,
ith  Strategy  3  still  expected  to  result  in  the  longest  period
f  seizure  freedom.
iscussion
his  paper  has  sought  to  address  the  limitations  in  the
xisting  literature  addressing  added  value  of  imaging
echnologies  by  considering  the  cost-effectiveness  of  pre-
urgical  workup  strategies  related  to  FDG—PET.  The  model
eveloped  was  based  on  the  best  available  clinical  and
conomic  evidence  identiﬁed  at  the  time  of  funding  using
ystematic  reviews.  The  results  of  the  main  analysis  found
hat  the  use  of  FDG—PET  for  those  patients  in  whom
he  decision  to  proceed  to  surgery  was  unclear  following
ideo  EEG  and  routine  MRI,  followed  by  invasive  EEG  for
atients  with  indeterminate  FDG—PET  results  (Strategy  3)
ppeared  the  most  cost-effective  strategy  at  conventional
ost-effectiveness  thresholds  of  £20,000  to  £30,000  per
ALY.  However,  when  the  beneﬁts  of  surgery  were  assumed
o  last  for  only  one  year,  as  represented  by  the  scenario,  the





Table  2  Descriptive  results  (base-case  and  alternative  scenario).
Strategy  Probability  of  having  surgery  Probability  of  b
Main  analysis
Strategy  1  0.00  0.08  
Strategy 2 0.56  0.44  
Strategy 3 0.68 0.52  
Alternative  scenario  (no  long-term  beneﬁts  of  surgery)
Strategy  1  0.00  0.08  
Strategy 2  0.56  0.44  
Strategy 3  0.68  0.52  0.04  32,876  0.27  0.39
DG—PET  became  less  apparent.  Since  the  completion  of
his  research  further  studies  have  been  published  relating
o  the  long  term  clinical  evidence  around  seizure  freedom
Edelvik  et  al.,  2013;  Hemb  et  al.,  2013),  while  these  stud-
es  have  not  been  included  in  the  model  their  ﬁndings  are
onsistent  with  the  modelled  approach,  strengthening  the
ndings  of  our  analysis.
We  consider  that  the  results  of  this  analysis  are  impor-
ant  in  several  respects.  First,  they  provide  a  clear  indication
hat  some  form  of  non-invasive  testing  after  an  initially  dis-
ordant  MRI  and  video-EEG  appears  cost-effective,  and  that
he  value  of  subsequent  invasive-EEGs  is  closely  linked  to
he  maintenance  of  beneﬁts  after  surgery.  Second,  as  dis-
ussed  by  Gazelle  et  al.  (2005)  the  model  demonstrates  that
he  added  value  of  the  visualisation  strategies  is  inextrica-
ly  linked  both  to  their  impact  on  the  decision  to  proceed  to
urgery  and  the  cost-effectiveness  of  the  subsequent  treat-
ents.
Our  research  has,  additionally,  highlighted  signiﬁcant
imitations  in  the  literature  around  the  pre-surgical  workup
or  epilepsy  surgery,  with  only  one  paper  deemed  to  have
ppropriately  collected  and  reported  the  value  to  the
ecision  maker  of  each  additional  medical  investigation.
Uijl  et  al.,  2007) Our  paper,  therefore,  provides  an  impor-
ant  stepping  stone  from  the  previous  work  conducted  by
uthors  such  as  Uijl  et  al.  (2005),  Burch  et  al.  (2012b)
n  the  evaluation  of  added  value  of  imaging  technologies
n  the  pre-surgical  workup  of  epilepsy  surgery.  However,
he  analysis  represents  a  simpliﬁcation  of  the  large  range
f  imaging  modalities  available  to  clinicians,  such  as























UThe  added  clinical  and  economic  value  of  diagnostic  testing
magnetoencephalography  scans,  and  is  unable  to  consider
the  role  of  factors  such  as  the  use  of  repeated  MRIs,  a
direct  result  of  the  lack  of  literature  accurately  considering
added  value  of  additional  investigations  to  the  clinician.
Finally  our  analysis  makes  the  important  link  in  the  exist-
ing  stages  of  the  evidence  hierarchy  by  constructing  a  robust
decision  model  able  to  assess  the  added  value  of  a  medi-
cal  imaging  technology  through  the  use  of  cost-effectiveness
evaluation.  This  is  the  natural  development  of  previous  stud-
ies  assessing  the  clinical  added  value  of  a  visualisation  test.
(Burch  et  al.,  2012b)  As  such  the  ﬁndings  of  this  research
are  of  relevance  to  areas  beyond  this  case  study,  having
demonstrated  the  proper  and  complete  application  of  the
framework  for  analysis  laid  out  by  Fryback  and  Thornbury
(1991),  Schaafsma  et  al.  (2009).
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